|
1
|
McKinney PA, Feltbower RG, Brocklebank JT
and Fitzpatrick MM: Time trends and ethnic patterns of childhood
nephrotic syndrome in Yorkshire, UK. Pediatr Nephrol. 16:1040–1044.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Tarshish P, Tobin JN, Bernstein J and
Edelmann CM Jr: Prognostic significance of the early course of
minimal change nephrotic syndrome: report of the International
Study of Kidney Disease in Children. J Am Soc Nephrol. 8:769–776.
1997.PubMed/NCBI
|
|
3
|
Hodson EM, Willis NS and Craig JC:
Non-corticosteroid treatment for nephrotic syndrome in children.
Cochrane Database Syst Rev. 1:CD0022902008.PubMed/NCBI
|
|
4
|
Tokunaga M, Saito K, Kawabata D, Imura Y,
Fujii T, Nakayamada S, Tsujimura S, Nawata M, Iwata S, Azuma T, et
al: Efficacy of rituximab (anti-CD20) for refractory systemic lupus
erythematosus involving the central nervous system. Ann Rheum Dis.
66:470–475. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Iijima K: Rituximab for childhood
refractory nephrotic syndrome. Pediatr Int. 53:617–621. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ravani P, Ponticelli A, Siciliano C,
Fornoni A, Magnasco A, Sica F, Bodria M, Caridi G, Wei C,
Belingheri M, et al: Rituximab is a safe and effective long-term
treatment for children with steroid and calcineurin
inhibitor-dependent idiopathic nephrotic syndrome. Kidney Int.
84:1025–1033. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kamei K, Ito S, Nozu K, Fujinaga S,
Nakayama M, Sako M, Saito M, Yoneko M and Iijima K: Single dose of
rituximab for refractory steroid-dependent nephrotic syndrome in
children. Pediatr Nephrol. 24:1321–1328. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Gulati A, Sinha A, Jordan SC, Hari P,
Dinda AK, Sharma S, Srivastava RN, Moudgil A and Bagga A: Efficacy
and safety of treatment with rituximab for difficult
steroid-resistant and -dependent nephrotic syndrome: Multicentric
report. Clin J Am Soc Nephrol. 5:2207–2212. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Iijima K, Sako M, Nozu K, Mori R, Tuchida
N, Kamei K, Miura K, Aya K, Nakanishi K, Ohtomo Y, et al: Rituximab
for Childhood-onset Refractory Nephrotic Syndrome (RCRNS) Study
Group: Rituximab for childhood-onset, complicated, frequently
relapsing nephrotic syndrome or steroid-dependent nephrotic
syndrome: a multicentre, double-blind, randomised,
placebo-controlled trial. Lancet. 384:1273–1281. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Fujinaga S, Hirano D, Nishizaki N, Kamei
K, Ito S, Ohtomo Y, Shimizu T and Kaneko K: Single infusion of
rituximab for persistent steroid-dependent minimal-change nephrotic
syndrome after long-term cyclosporine. Pediatr Nephrol. 25:539–544.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kidney Disease Improving Global Outcomes:
KDIGO Clinical Practice Guideline for Glomerulonephritis. Kidney
Int Suppl. 2:139–274. 2012.
|
|
12
|
Schulman SL, Kaiser BA, Polinsky MS,
Srinivasan R and Baluarte HJ: Predicting the response to cytotoxic
therapy for childhood nephrotic syndrome: superiority of response
to corticosteroid therapy over histopathologic patterns. J Pediatr.
113:996–1001. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Prytuła A, Iijima K, Kamei K, Geary D,
Gottlich E, Majeed A, Taylor M, Marks SD, Tuchman S, Camilla R, et
al: Rituximab in refractory nephrotic syndrome. Pediatr Nephrol.
25:461–468. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sun L, Xu H, Shen Q, Cao Q, Rao J, Liu HM,
Fang XY and Zhou LJ: Efficacy of rituximab therapy in children with
refractory nephrotic syndrome: a prospective observational study in
Shanghai. World J Pediatr. 10:59–63. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ito S, Kamei K, Ogura M, Udagawa T,
Fujinaga S, Saito M, Sako M and Iijima K: Survey of rituximab
treatment for childhood-onset refractory nephrotic syndrome.
Pediatr Nephrol. 28:257–264. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Tellier S, Brochard K, Garnier A, Bandin
F, Llanas B, Guigonis V, Cailliez M, Pietrement C, Dunand O,
Nathanson S, et al: Long-term outcome of children treated with
rituximab for idiopathic nephrotic syndrome. Pediatr Nephrol.
28:911–918. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sellier-Leclerc AL, Baudouin V, Kwon T,
Macher MA, Guérin V, Lapillonne H, Deschênes G and Ulinski T:
Rituximab in steroid-dependent idiopathic nephrotic syndrome in
childhood - follow-up after CD19 recovery. Nephrol Dial Transplant.
27:1083–1089. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kemper MJ, Gellermann J, Habbig S, Krmar
RT, Dittrich K, Jungraithmayr T, Pape L, Patzer L, Billing H, Weber
L, et al: Long-term follow-up after rituximab for steroid-dependent
idiopathic nephrotic syndrome. Nephrol Dial Transplant.
27:1910–1915. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ravani P, Magnasco A, Edefonti A, Murer L,
Rossi R, Ghio L, Benetti E, Scozzola F, Pasini A, Dallera N, et al:
Short-term effects of rituximab in children with steroid- and
calcineurin-dependent nephrotic syndrome: a randomized controlled
trial. Clin J Am Soc Nephrol. 6:1308–1315. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sellier-Leclerc AL, Macher MA, Loirat C,
Guérin V, Watier H, Peuchmaur M, Baudouin V and Deschênes G:
Rituximab efficiency in children with steroid-dependent nephrotic
syndrome. Pediatr Nephrol. 25:1109–1115. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
El-Reshaid K, Sallam HT, Hakim AA,
Al-Attiyah R and EI-Reshaid K: Rituximab in treatment of idiopathic
glomerulopathy. Saudi J Kidney Dis Transpl. 23:973–978. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Samarghitean C, Väliaho J and Vihinen M:
Online registry of genetic and clinical immunodeficiency diagnostic
laboratories, IDdiagnostics. J Clin Immunol. 24:53–61. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kyrieleis HA, Löwik MM, Pronk I, Cruysberg
HR, Kremer JA, Oyen WJ, van den Heuvel BL, Wetzels JF and
Levtchenko EN: Long-term outcome of biopsy-proven, frequently
relapsing minimal-change nephrotic syndrome in children. Clin J Am
Soc Nephrol. 4:1593–1600. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kemper MJ, Meyer-Jark T, Lilova M and
Müller-Wiefel DE: Combined T- and B-cell activation in childhood
steroid-sensitive nephrotic syndrome. Clin Nephrol. 60:242–247.
2003. View
Article : Google Scholar : PubMed/NCBI
|
|
25
|
Cho BS, Yoon SR, Jang JY, Pyun KH and Lee
CE: Up-regulation of interleukin-4 and CD23/FcepsilonRII in minimal
change nephrotic syndrome. Pediatr Nephrol. 13:199–204. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kimata H, Fujimoto M and Furusho K:
Involvement of interleukin (IL)-13, but not IL-4, in spontaneous
IgE and IgG4 production in nephrotic syndrome. Eur J Immunol.
25:1497–1501. 1995. View Article : Google Scholar : PubMed/NCBI
|
